Drug Profile


Alternative Names: GL-ONC1; GLV-1h68

Latest Information Update: 03 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Genelux Corporation
  • Developer Genelux Corporation; Memorial Sloan-Kettering Cancer Center
  • Class Antineoplastics; Oncolytic viruses
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Ovarian cancer
  • Phase I/II Peritoneal cancer
  • Phase I Head and neck cancer; Malignant pleural effusion; Solid tumours

Most Recent Events

  • 07 Aug 2017 Phase-II clinical trials in Ovarian cancer (Second-line therapy or greater, Monotherapy) in USA (Intraperitoneal) (NCT02759588)
  • 01 May 2016 Phase-I clinical trials in Ovarian cancer (Second-line therapy or greater) in USA (Intraperitoneal) (NCT02759588)
  • 29 Apr 2016 Genelux Corporation plans a phase Ib trial for Ovarian cancer (Second-line therapy or greater) in USA (Intraperitoneal) (NCT02759588)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top